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ABSTRACT
Background: Drug development in sarcoma has been hampered by the rarity 
and heterogeneity of the disease and lack of predictive biomarkers to therapies. 
We assessed protein expression and gene alterations in a large number of bone 
and soft tissue sarcomas in order to categorize the molecular alterations, identify 
predictive biomarkers and discover new therapeutic targets. Methods: Data from 
sarcoma specimens profiled for protein expression, gene amplification/translocation 
and DNA sequencing was reviewed. Results: 2539 sarcoma specimens of 22 subtypes 
were included. TOPO2A was the most overexpressed protein at 52.8%. There was 
overexpression or loss of other sarcoma relevant proteins such as SPARC, PTEN and 
MGMT. Approximately 50% of the sarcomas expressed PD-L1 by IHC and presented 
with PD-1+ TILs, notably the LMS, chondrosarcomas, liposarcomas and UPS. Gene 
amplification/rearrangement of ALK, cMYC, HER2, PIK3CA, TOPO2A and cMET was 
relatively uncommon. EGFR gene amplification occurred at a rate of 16.9%. DNA 
sequencing of 47 genes identified mutations in 47% of the samples. The most 
commonly mutated genes were TP53 (26.3%) and BRCA2 (17.6%). Overexpression 
of TOPO2A was associated with TP53 mutation (P = 0.0001). Conclusion: This data 
provides the landscape of alterations in sarcoma. Future clinical trials are needed to 
validate these targets.
INTRODUCTION
Sarcomas are a rare, heterogeneous group of 
mesenchymal tumors. With over 100 subtypes, a 
single therapeutic strategy for this group of cancers is 
unfeasible. For patients with advanced disease, the 
selection of therapy is based on the specific sarcoma 
subtype as well as the patient’s fitness to receive 
aggressive chemotherapy. With this approach, median 
overall survival for patients with advanced bone and 
soft tissue sarcomas (STS) remains under two years 
[1]. Sarcomas can be classified according to the genetic 
alterations involved in their development: those with 
oncogenic somatic mutations [e.g. gastrointestinal 
stromal tumors (GIST)], those with DNA copy number 
alterations (e.g. dedifferentiated liposarcomas), and 
those with recurrent chromosomal translocations 
resulting in abnormal fusion proteins (e.g. synovial 
sarcomas). More commonly, sarcomagenesis is a result 
of complex chromosomal abnormalities, as in the case 
of leiomyosarcomas and high grade undifferentiated 
pleomorphic sarcomas [2].
Analyses of genetic alterations in sarcoma have 
generally focused on particular subtypes [3, 4] and 
frequently employ limited methodologies. Data from 
large scale, systematic genomic profiling of sarcomas 
is limited. Barretina and colleagues characterized 207 
sarcoma specimens, including seven different subtypes, 
by DNA sequence, copy number alterations and mRNA 
expression. They were able to identify potentially 
druggable PIK3CA mutations in 18% of myxoid 
liposarcomas [5]. Conversely, a separate series, by Cote 
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and colleagues found that when solely using DNA hotspot 
analysis or whole exome sequencing, mutations were 
rare and there was no pattern of alterations noted within 
sarcoma subtypes [6].
Protein biomarkers have been studied for many 
decades, in an attempt to predict which tumors will 
respond to what therapies. This is best highlighted in 
the breast cancer field, where the proteins estrogen 
receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor (HER2) have been 
well established as prospective treatment response 
biomarkers [7, 8]. To date, a large analysis for common 
chemotherapy associated biomarkers has not been 
performed across a large group of sarcomas. A detailed 
mapping of the therapy associated biomarkers will allow 
for identification of both targets and histologies that may 
respond to a particular drug, in order to design better 
clinical trials [9].
Using a registry of 2539 patients with bone and soft 
tissue sarcomas we have catalogued changes in protein 
expression, gene amplification/translocation, and somatic 
mutations. Herein we describe these findings with the goal 
of systematically characterizing the molecular alterations 
in a variety of sarcoma subtypes, identifying potential 
biomarkers of sensitivity to chemotherapy and targeted 
agents, and potentially discovering novel therapeutic 
targets.
RESULTS
Population
2539 sarcoma specimens encompassing 61 bone and 
STS subtypes were profiled. These included 22 standard 
histologies, and an “other” (n = 454) category, that 
included sarcoma NOS (n = 251) and spindle cell 
tumor (n = 103), as well as 37 sarcoma subtypes that 
had fewer than 10 cases. The most common histology 
was leiomyosarcoma (LMS) (n = 751) with 401 of 
these uterine, followed by liposarcoma (n = 220) and 
undifferentiated pleomorphic sarcoma [UPS (formally 
malignant fibrous histiocytoma) (n = 166)]. Of the 
77 angiosarcomas, 14 were of breast origin. 862 samples 
were known to be from a metastatic site. The median age 
of the population was 53 (range: 1–92). 62% of the cases 
were from females. Up to 2434 samples were profiled 
by IHC, 1048 by FISH/CISH, 591 by NGS and 1250 by 
Sanger sequencing. 530 samples were profiled on all three 
platforms (IHC, FISH/CISH and either NGS or Sanger 
sequencing).
Protein biomarkers
TOPO2A overexpression, an anthracycline 
associated response biomarker, was noted in 52.8% 
of the sarcomas and in greater than 60% of MPNST, 
angiosarcoma, LMS, rhabdomyosarcoma and UPS. High 
expression of TOPO2A has been previously reported 
at a rate of 50% in STS, when median percentage was 
chosen as the cutoff to discriminate between high and 
low expressing tumors, rather than criteria previously 
described in breast cancer [10, 11]. Overexpression 
of serum protein acidic and rich in cysteine (SPARC), 
a biomarker for albumin bound paclitaxel, was seen in 
35.9% of the cases, especially in over 60% of epithelioid 
hemangioendothelioma (EHE) and chondrosarcoma 
(notably conventional chondrosarcoma), as well as 
48.7% of angiosarcomas. A previous study of SPARC 
expression by IHC, noted a rate of high SPARC staining 
in 56% of specimens, but given the small sample size 
(n = 27), specific histology correlations could not be 
made [12]. Low MGMT expression, a temozolomide 
associated biomarker, was noted in a variety of sarcomas 
including alveolar soft part sarcoma (21 ASPS), desmoid, 
EHE, perivascular epithelioid cell tumor (PEComa), 
endometrial stromal sarcoma (ESS), giant cell tumor, 
liposarcoma, LMS, malignant peripheral nerve sheath 
tumor (MPNST), osteosarcoma and UPS. There was 
low expression of MGMT in 65.3% of the sarcomas 
overall. Previous studies have only considered nuclear 
staining positive, and have reported a much lower rate of 
MGMT loss in LMS and other STS subtypes, therefore 
validation of a particular method is required to determine 
the predictive value in STS [13]. PTEN loss was seen 
in 38.6% of the sarcomas, most commonly in epithelioid 
sarcoma, chordoma, alveolar rhabdomyosarcoma and 
osteosarcoma. PTEN loss was only noted in 32.2% of 
non-uterine LMS and 37.6% of uterine LMS. Previous 
work on complex genomic sarcomas such as LMS, 
UPS and MPNST have reported rates of PTEN loss 
in 29%–44% of the sarcomas, [14, 15] but data on the 
expression of PTEN in rarer sarcomas is lacking. cKIT 
overexpression was noted in 28.5% of angiosarcoma, 
19% of desmoplastic small round cell tumor (DSRCT) 
and 37.3% of Ewing’s sarcoma. There were 2 cases 
of sclerosing rhabdomyosarcoma, both of which 
overexpressed cKIT. This is a rare sarcoma whose 
treatment paradigm is not yet clearly defined. PDGFRA 
was overexpressed in 22.1% of the sarcomas, including, 
38.5% of angiosarcoma, 33.3% of liposarcoma, 33.3% 
of fibrosarcoma, 31.8% of Ewing’s sarcoma, 30.8% of 
chondrosarcoma, 27.8% of osteosarcoma, 27.8% of 
UPS and 18.3% of non-uterine LMS. High PDGFRA 
expression has been described previously in many of these 
tumors [16–18]. In a series by Rodrigo and colleagues 
HER2 protein expression by IHC was negative in all 
sarcoma samples [10]. HER2 overexpression was noted 
in only one case in this series, an ESS, confirming that 
this is not an important pathway in sarcoma (Figure 1a 
and 1b and Supplementary Table 1).
AR overexpression was seen in 18.3–54.2% of 
myxoid chondrosarcoma, DSRCT, pleomorphic and 
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well-differentiated liposarcoma, ESS and LMS. ER 
overexpression was seen in 47.8% of ESS, 23.0% of 
non-uterine LMS, 60.3% of uterine LMS and 23.5% 
of PEComas (Figure 1c and Supplementary Table 1). 
The  rates of ER overexpression in uterine LMS appear 
similar to previous studies [19, 20]. This data also 
confirms the rate of ER positivity in non-uterine LMS 
at approximately 20% with a much larger number of 
cases [21].
Overall, approximately 50% of the sarcomas 
expressed PD-L1 by IHC and presented with PD-1+ TILs, 
similar to other series [22]. Sarcomas with sufficient 
number of cases and overexpression of these proteins 
included LMS, chondrosarcoma, liposarcoma and UPS. 
Only 4 cases of synovial sarcoma were available for 
testing, 1 of which had simultaneous overexpression 
of PD-L1 and presence of PD-1+ TILs (Figure 1d and 
Supplementary Table 2). This rate is lower than published 
literature [22].
FISH/CISH
The most commonly amplified gene was EGFR 
at a rate of 16.9% overall. This was especially noted in 
histologies such as DSRCT, LMS, MPNST, osteosarcoma 
and UPS at a rate of 20% or higher. Smaller sarcoma 
series have suggested a lower rate of amplification 
overall (3.5%), most commonly in UPS [23]. In series 
focusing on MPNST specifically, the rate of EGFR gene 
amplification by FISH was 28–37% [24, 25]. None of the 
synovial sarcomas in our series demonstrated genomic 
amplification of EGFR, consistent with previous work 
[26]. Amplification of the ALK, cMYC, PIK3CA and 
TOPO2A genes were relatively uncommon events. cMET 
was amplified in 5–6% of osteosarcoma and synovial 
sarcomas. HER2 was amplified in 5.6% of MPNST 
(Table 1).
DNA sequencing
591 samples were profiled by NGS and 1250 
by Sanger sequencing. 47% of the samples had an 
identifiable mutation in 35 of the 47 genes analyzed. 
The most commonly mutated genes overall were 
TP53 (26.3%) and BRCA2 (17.6%). Histologies 
carrying mutations at a frequency of ≥ 5% included: 
angiosarcoma (APC, BRAF, GNA11, HRAS KDR, KRAS, 
NRAS), chondrosarcoma [IDH1 (conventional and 
unknown/other), PTEN (myxoid), cMET (conventional 
and mesenchymal)], desmoid (APC, CTNNB1, STK11), 
ESS (AKT1, cMET, FGFR2, GNAS, KRAS, RET, 
SMO), Ewing’s sarcoma (APC, ATM, HNF1A, PTEN), 
fibrosarcoma (KRAS), giant cell tumor (KRAS), myxoid 
liposarcoma (AKT1, ATM, cMET, JAK3, PIK3CA, 
PTEN), dedifferentiated liposarcoma (HNF1), well-
differentiated liposarcoma (cMET), LMS (BRCA2, RB1), 
MPNST (BRAF V600E), osteosarcoma (cKIT, FLT3), 
rhabdomyosarcoma [FLT3 (pleomorphic), PIK3CA 
(uknown/other), PTEN (unknown/other), PTPN11 
(alveolar), SMARCB1 (unknown/other)], solitary fibrous 
tumor (cKIT, PDGFRA, PIK3CA, STK11), synovial 
sarcoma (ABL1, ATM, BRAF, cKIT, KDR, MLH1) and 
UPS (KDR, PIK3CA). BRCA2 mutations were seen in 
17% of LMS, both uterine and non-uterine. PTEN and 
RB1 mutations were noted exclusively in non-uterine 
LMS and not in those of uterine origin. NRAS mutations 
were detected in 20% of non-breast angiosarcomas, 
and were not found in those of breast origin. The 
PIK3CA mutations noted in liposarcoma (5 cases) were 
found in 4 myxoid liposarcomas and in 1 high grade 
pleomporphic liposarcoma. No EGFR mutations were 
detected in our series (Figure 2a–d and Supplementary 
Table 3). One case of MPNST carried a G12V KRAS 
mutation. We detected BRAF, PTEN, p53 and NRAS 
mutations in angiosarcoma specimens, not previously 
described in the literature [4].
Biomarker associations
There was relatively low concordance across 
platforms for individual genes or proteins (Table 2). For 
example, cKIT overexpression by IHC was infrequently 
associated with cKIT mutations. This is in contrast to the 
scenario in GIST, where more than 80% of cases carry an 
activating mutation in the KIT gene [27]. In our series, 
overexpression of TOPO2A by IHC was not associated 
with TOPO2A gene amplification, similar to some series 
in breast cancer and in contrast to others [28, 29]. We also 
examined the association of TP53 or PIK3CA mutations 
with other alterations (Table 3 and Table 4). We noted 
that 85.8% of samples demonstrated both TOPO2A 
expression by IHC and TP53 mutation (P value = 
0.0001). Three patient tumor samples had both a PIK3CA 
mutation and PTEN loss by IHC (myxoid liposarcoma, 
rhabdomyosarcoma and sarcoma, NOS). Two patient 
samples had EGFR amplification and KRAS mutation 
(1 MFH and 1 ESS).
DISCUSSION
This data set represents the largest number of 
sarcoma cases molecularly profiled to date. We observed 
that TOPO2A was overexpressed in approximately 50% 
of sarcomas, without associated gene amplification, 
most commonly in the angiosarcomas, LMS, 
MPNST, rhabdomyosarcoma and UPS. Indeed, 
amplification of the TOPO2A gene has not reliably 
predicted increased protein levels of TOPO2A in other 
cancers [11, 29, 30].
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Figure 1: Protein biomarker expression by IHC. A. Soft tissue sarcomas B. Bone sarcomas C. Hormone receptors D. PD-1,  
PD-L1. ASPS = alveolar soft part sarcoma, DSRCT = desmoplastic small round cell tumor, EHE = epithelioid hemangioendothelioma 
ESS = endometrial stromal sarcoma, SFT = solitary fibrous tumor, LMS = leiomyosarcoma, UPS = undifferentiated pleomorphic sarcoma, 
MPNST = malignant peripheral nerve sheath tumor, PEComa = perivascular epithelioid cell tumor.
Table 1: FISH/CISH by histology
Gene**
Histology* ISH cMET ISH EGFR ISH HER2
All (n = 2539) Total Positive 20 181 9
Total Cases 761 1072 925
% Positive 2.6 16.9 1.0
Angiosarcoma (n = 77) Total Positive 0 1 0
Total Cases 26 34 33
% Positive 0.0 2.9 0.0
Chondrosarcoma (n = 97) Total Positive 1 2 1
Total Cases 32 24 42
% Positive 3.1 8.3 2.4
(Continued )
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Gene**
Histology* ISH cMET ISH EGFR ISH HER2
Clear cell sarcoma (n = 16) Total Positive 0 1 0
Total Cases 4 8 4
% Positive 0.0 12.5 0.0
DSRCT (n = 8) Total Positive 0 2 0
Total Cases 11 10 15
% Positive 0.0 20.0 0.0
ESS (n = 91) Total Positives 0 4 1
Total Cases 33 50 31
% Positive 0.0 8.0 3.2
Ewing’s sarcoma (n = 83) Total Positive 0 2 0
Total Cases 23 30 27
% Positive 0.0 6.7 0.0
Fibrosarcoma (n = 63) Total Positive 0 5 0
Total Cases 21 33 21
% Positive 0.0 15.2 0.0
Giant cell tumor (n = 13) Total Positive 0 2 0
Total Cases 3 7 4
% Positive 0.0 28.6 0.0
Liposarcoma (n = 220) Total Positive 3 14 0
Total Cases 62 80 93
% Positive 4.8 17.5 0.0
Myxoid (n = 46) Total Positive 1 0 0
Total Cases 14 15 18
% Positive 7.1 0.0 0.0
Dedifferentiated (n = 77) Total Positive 0 1 0
Total Cases 24 28 41
% Positive 0.0 3.6 0.0
Well-differentiated (n = 31) Total Positive 0 5 0
Total Cases 11 12 13
% Positive 0.0 41.7 0.0
(Continued )
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Gene**
Histology* ISH cMET ISH EGFR ISH HER2
Pleomorphic (n = 30) Total Positive 2 5 0
Total Cases 7 8 10
% Positive 28.6 62.5 0.0
Other/Unknown (n = 36) Total Positive 0 3 0
Total Cases 6 17 11
% Positive 0.0 17.6 0.0
LMS (nonuterine) (n = 350) Total Positive 4 27 3
Total Cases 112 128 137
% Positive 3.6 21.1 2.2
LMS (uterine) (n = 401) Total Positive 4 43 1
Total Cases 96 220 106
% Positive 4.2 19.5 0.9
MPNST (n = 36) Total Positive 0 4 1
Total Cases 13 14 18
% Positive 0.0 28.6 5.6
Osteosarcoma (n = 95) Total Positive 1 9 0
Total Cases 18 46 24
% Positive 5.6 19.6 0.0
PEComa (n = 17) Total Positive 0 2 0
Total Cases 9 7 9
% Positive 0.0 28.6 0.0
Rhabdomyosarcoma (n = 82) Total Positive 0 4 1
Total Cases 27 26 36
% Positive 0.0 15.4 2.8
Alveolar (n = 18) Total Positive 0 1 0
Total Cases 1 4 3
% Positive 0.0 25.0 0.0
Embryonal (n = 19) Total Positive 0 0 0
Total Cases 7 8 6
% Positive 0.0 0.0 0.0
Pleomorphic (n = 9) Total Positive 0 0 0
Total Cases 5 1 7
% Positive 0.0 0.0 0.0
Other/Unknown (n = 36) Total Positive 0 3 1
Total Cases 14 12 20
% Positive 0.0 25.0 5.0
(Continued )
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Anthracylines have served as a cornerstone for the 
treatment of sarcomas for decades. Response rates to 
single agent doxorubicin range from 9% to 27% [31, 32], 
with clinical benefit in approximately 60% of patients 
[33]. The mechanisms related to the lack of benefit seen 
in some patients are not entirely clear. TOPO2A is an 
important target for anthracyclines and its inhibition leads 
to double-strand DNA breaks and cell death. In breast 
cancer, TOPO2A protein expression by IHC has been 
correlated with response to anthracyclines [34], however 
this has been confounded by the co-expression of HER2. 
In sarcoma, a retrospective study of TOPO2A expression 
in 78 patients who underwent neoadjuvant therapy with 
an anthracycline, found that histologic response was 
positively correlated with high expression of TOPO2A 
[10]. This finding requires prospective validation. 
Although previous work has suggested overexpression of 
HER2 in approximately 50% of synovial sarcomas [26], 
none of the sarcoma specimens in this series co-expressed 
HER2. These findings also suggest that TOPO2A protein 
expression is not controlled by gene copy number, but 
through RNA or post-translational mechanisms. Our 
analysis also found an association between TOPO2A 
overexpression by IHC and TP53 mutation status. Indeed, 
in some studies, breast tumors containing TP53 mutations 
are exquisitely sensitive to anthracycline based therapy 
[35]. It has been postulated and shown in TP53 wild type 
xenograft models that upon treatment with doxorubicin, 
there is induction of a senescent phenotype leading to 
cell cycle arrest and subsequent resistance to treatment 
[36, 37]. This mutational status could therefore serve as a 
biomarker for sensitivity to anthracyclines in sarcoma and 
requires further study.
SPARC is a serum albumin-binding glycoprotein 
secreted by endothelial cells. It is hypothesized that 
tumoral SPARC could serve as a biomarker for sensitivity 
to the albumin-bound nanopartical of paclitaxel NAB-
paclitaxel. In pancreatic cancer, SPARC overexpression 
was correlated with response rate to nab-paclitaxel and 
prolonged progression free survival [38]. Clinically, 
angiosarcomas and EHE are essentially the only sarcoma 
subtypes where single agent taxanes are of benefit [39]. 
Though, SPARC expression has been assessed in sarcoma 
specimens, only 1 case of angiosarcoma has previously 
been evaluated and was found to have high expression 
of SPARC [12]. In our study, interestingly, SPARC 
was overexpressed in angiosarcoma, chondrosarcoma 
and EHE. A clinical trial of nab-paclitaxel in a wide 
variety of bone and soft tissue sarcomas did not meet 
its primary endpoint. However, this study did not assess 
for SPARC status or include patients with angiosarcoma 
or EHE [40]. MGMT gene silencing through promotor 
Gene**
Histology* ISH cMET ISH EGFR ISH HER2
SFT (n = 56) Total Positive 0 1 0
Total Cases 11 28 18
% Positive 0.0 3.6 0.0
Synovial sarcoma (n = 70) Total Positive 1 0 0
Total Cases 19 31 21
% Positive 5.3 0.0 0.0
UPS (n = 166) Total Positive 2 30 0
Total Cases 54 76 66
% Positive 3.7 39.5 0.0
Other (n = 454) Total Positive 4 28 1
Total Cases 156 182 177
% Positive 2.6 15.4 0.6
DSRCT = desmoplastic small round cell tumor, ESS = endometrial stromal sarcoma, LMS = leiomyosarcoma,  
UPS/MFH = undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, MPNST = malignant peripheral 
nerve sheath tumor, PEComa = perivascular epithelioid cell tumor, SFT = solitary fibrous tumor,
*Histologies with no amplification of genes tested: alveolar soft part sarcoma, chordoma, desmoid, epithelioid 
hemangioendothelioma, epithelioid sarcoma.
**PIK3CA – 3/9 cases amplified( LMS, osteosarcoma, other); TOPO2A – 2/118 cases amplified(LMS, other); cMYC – 1/18 
cases amplified(osteosarcoma); ALK – 1/65 cases amplified (LMS).
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methylation confers sensitivity to the alkylating agents 
in glioblastoma [41]. Previous work has suggested that 
20% of STS have MGMT loss by IHC and 8% have both 
promoter methylation and negative IHC nuclear staining. 
Response to temozolomide has been noted in a patient 
with a resistant undifferentiated high grade sarcoma whose 
tumor demonstrated MGMT promoter methylation and 
protein loss by IHC [42].
Targeted therapy has improved outcomes of 
patients with solid tumors such as lung and kidney cancer. 
Pazopanib remains the only FDA approved targeted 
therapy in STS, as other trials of novel agents have 
largely been unsuccessful when tested in a broad- range of 
sarcomas. Biomarkers predicting response would therefore 
be of utility. The PI3-kinase pathway is of great interest 
in sarcoma and cancer in general. Previous studies have 
shown PTEN partial genomic loss and loss of protein 
expression in LMS. Gibault and colleagues showed that 
partial loss of PTEN gene by array-comparative genomic 
hybridization (a-CGH) occurs in 39% of sarcomas with 
complex genomics and that this may be sufficient for a 
pathologic phenotype [14]. On the other hand, PTEN 
promoter methylation appears to be an uncommon event 
and may not play a major role in down-regulation of 
PTEN expression [14, 15]. In our study PTEN loss was 
most notable in the chordomas, epithelioid sarcomas, 
alveolar rhabdomyosarcomas and osteosarcomas. 
Though loss was noted in the LMS cohort, this was 
only seen in about 35% of the cases. Disappointingly, 
targeting this pathway with mTOR inhibitors has been 
unsuccessful clinically [43], possibly owing to the fact that 
preselection of tumors with alterations in the PI3-kinase 
pathway was not required for trial enrollment. Overall, 
the rate of PIK3CA and PTEN mutations was low in our 
series. PTEN mutations were most commonly seen in 
chondrosarcomas (7.7%), myxoid liposarcomas (16.7%), 
Figure 2: DNA sequencing in sarcoma. A. Most frequent mutation (%) B. Mutation type C. Mutations in STS D. Mutations in 
bone sarcoma. ASPS = alveolar soft part sarcoma, DSRCT = desmoplastic small round cell tumor, ESS = endometrial stromal sarcoma, 
SFT = solitary fibrous tumor, LMS = leiomyosarcoma, UPS = undifferentiated pleomorphic sarcoma, MPNST = malignant peripheral nerve 
sheath tumor, PEComa = perivascular epithelioid cell tumor.
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Ewing’s sarcoma and rhabdomyosarcoma (6.3%). Previous 
work has demonstrated PIK3CA mutations in 14–18% of 
myxoid and round cell liposarcoma [3, 5]. In our series, 
PIK3CA mutations were most commonly seen in myxoid 
liposarcoma (23.5%), as well as in rhabdomyosarcoma 
(7.4%), solitary fibrous tumor (6.3%) and UPS (5.5%). 
We had 1 case of myxoid liposarcoma with both PTEN loss 
by IHC and PIK3CA mutation, not previously described 
in the literature [3]. We also detected pathogenic PTEN 
mutations in angiosarcoma specimens, which have not 
Table 2: Concordance across platforms
N positive 
concordance/N
IHC+(%) FISH amplified (%) Mutation (%)
cKIT 0/23 65/1441 (4.5) NA 12/749 (1.6) All VUS*
cMET
1/751 (IHC/ISH)
0/442 (ISH/NGS)
1/567 (IHC/NGS)
43/970 (4.4) 20/761 (2.6)
15/588 (2.6)
All VUS*
EGFR
2/45 (IHC/ISH)
0/16 (ISH/NGS)
0/11 (IHC/NGS)
80/217 (36.9) 181/1072 (16.9) 0/608 (0)
HER2
0/910 (IHC/ISH)
0/518 (ISH/NGS)
0/555 (IHC/NGS
1/2409 (0.04) 
*Case with HER2 
overexpression was 
not tested on other 
platforms
9/925 (1.0) 0/573 (0)
PDGFR NA 135/610 (22.1) NA 1/581 (0)
PTEN 8/539 (IHC/NGS) Loss 910/2358 (38.6) NA
16/557(15 cases) (3.2) 
*8/15 cases with 
PTEN mutation had 
PTEN loss
*7/15 cases with 
mutation were VUS 
without PTEN loss
TOPO2A 0/36(IHC/FISH) 1117/2114 (52.8) 2/118 (1.7) NA
*VUS = variant of unknown significance
Table 3: Biomarker associations
PTEN 
Loss IHC
TOPO2 
IHC+
PTEN 
MT
cMET 
MT
IDH MT CTNNB1 
MT
APC MT KRAS 
MT
TP53wt 56/414 (13.5%)
226/396 
(57.1%)
9/407 
(2.2%)
8/427 
(1.9%)
5/430 
(1.2%)
13/430 
(3.0%)
11/429 
(2.6%)
7/429 
(1.6%)
TP53 mutated 22/135 (16.3%)
115/134 
(85.8%)
5/127 
(3.9%)
6/136 
(4.4%)
4/136 
(2.9%) 0/136 (0)
5/135 
(3.7%)
1/135 
(0.7%)
P value 0.48 0.0001 0.34 0.11 0.23 0.045 0.55 0.69
Table 4: Biomarker associations
TP53 MT (%) PTEN Loss IHC (%) TOPO2 IHC+ (%) PTEN MT (%)
PIK3CA mutated 5/20 (25.0%) 3/22 (13.6%) 14/20 (70.0%) 2/18 (11.1%)
PIK3CA WT 140/533 (26.3%) 143/781 (18.3%) 367/567 (64.7%) 13/529 (2.5%)
P value 1.0 0.78 0.81 0.08
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previously been described in the literature [4]. Finally, 
our data suggests the co-existence of PTEN and TP53 
mutations, as well as TP53 mutations and PTEN loss 
in sarcoma specimens. Indeed, it is known that there is 
considerable crosstalk between these two tumor suppressor 
genes [44, 45]. The prognostic effect of this phenomenon is 
not known in sarcoma; therefore validation against phase 
III clinical data is needed. Our data also confirmed the rate 
of ER positivity in LMS. A phase II study of the aromatase 
inhibitor letrozole in these patients has demonstrated 
clinical benefit [46]. On the other hand, though PDGFRA 
was overexpressed in many tumors consistent with 
previous work [16–18], phase II studies of imatinib in 
PDGFR- positive sarcomas failed to show benefit [18, 47].
Newer immunotherapies have demonstrated success 
in melanoma, kidney cancers and lung cancers, but have 
not yet been evaluated in sarcoma [48]. Currently of most 
interest are the PD-1 and PD-L1 inhibitors. Previous work 
has shown that both PD-1 and PD-L1 positivity were 
independent prognostic indicators for OS and EFS in 
sarcoma [22]. PD-1 positive tumor-infiltrating lymphocytes 
and PD-L1 expression in tumor cells were seen in 65% 
and 58% of STS cases respectively. Uncertainty remains 
as to the effectiveness of PD-L1 expression in tumor as 
a biomarker for sensitivity to the checkpoint inhibitors as 
patients with low or no expression of PD-L1 may still have 
a response and/or survival benefit [49]. PD-L1 expression 
was noted in the majority of chondrosarcomas, LMS, UPS 
and liposarcoma in our series.
Protein expression is a semi-quantitative, inclusive 
end-point. Changes in protein level may be a result of 
mutations, increased gene copy number, changes in 
gene expression, or biochemical responses within the 
cell to environmental factors. In other solid tumors, 
there is concordance between protein expression by 
IHC and mutation or gene amplification as in the cases 
of cKIT and HER2 respectively [50, 51]. However, 
discordance has been documented across solid tumors 
for cMET, TOP2A, and PTEN [30] , proposed to be due 
to downstream modulation of protein expression levels. 
There was relatively low concordance across platforms 
in our series, suggesting that protein levels of cKIT, 
cMET and TOPO2A may be regulated at the RNA or post 
translational level. On the other hand, IHC for certain 
proteins such as EGFR, is known to be unreliable, owing 
the antibodies and scoring system used [23]. In fact, a 
prior clinical trial of gefitinib in synovial sarcomas with 
enrollment limited to patients overexpressing EGFR 
by IHC was without responses to this agent. Twenty-
one percent of patients did have stable disease [52]. 
In addition, no EGFR mutations were detected in our 
sarcomas, consistent with other series [24]. Our data set 
suggests that EGFR gene amplification could be used 
instead of IHC as a biomarker for sensitivity to the EGFR 
inhibitors. This gene amplification was most notable in 
DSRCT, LMS, MPNST, osteosarcoma and UPS.
There are several limitations to this analysis. 
Though all specimens underwent pathology review to 
confirm a diagnosis of sarcoma, the specific subtype was 
determined by the submitting institution’s pathologist. 
This is problematic for non-specific diagnoses such as 
fibrosarcoma, which may in fact represent a heterogenous 
group of tumors. The lack of concordance across 
platforms observed in this series is of interest. This may be 
attributed, as in the case of EGFR, to the unreliability of 
IHC. In this case, it seems that copy number analysis may 
be more useful. On the other hand, the lack of concordance 
between cKIT activating mutations and increased protein 
expression suggests an inadequacy in the methodology 
used to detect these genetic alterations. In fact, there was 
a low frequency of actionable mutations detected in this 
series overall, suggesting that Hotspot analysis has limited 
scope in sarcoma and techniques such as whole exome 
sequencing should be explored. Despite these limitations 
in technique, there were a few noteworthy observations, 
including alteration of the RAF/RAS/MEK/ERK pathway 
in angiosarcoma. Finally, this analysis does not include 
details on treatment history and/or patient outcomes 
which would be useful as a first step in validation of these 
potential biomarkers.
These data represent a large analysis of molecular 
alterations by sarcoma subtype. Although there are 
limitations of this analysis, this data catalogue provides 
the groundwork for future clinical trials in sarcoma 
and highlights the need for the sarcoma community to 
prospectively validate tumor biomarkers in our clinical trials.
MATERIALS AND METHODS
Data from sarcoma specimens profiled on at least 
one platform by Caris Life Sciences from January 11, 2006 
through July 31, 2014 were included. Formalin fixed 
paraffin-embedded (FFPE) sarcoma samples were sent 
for analysis from treating physicians around the world 
(59 countries). The specific sarcoma histology was extracted 
from paperwork submitted by the treating physician. GIST 
was excluded, to limit the analysis to sarcomas without 
known therapeutic targets. Tumors were initially verified by 
a board certified pathologist for sufficient tumor presence 
and to confirm the diagnosis of sarcoma. Any sample 
reviewed and determined not to be a sarcoma was excluded 
from this cohort. Samples were subsequently analyzed 
using one or more of the profiling platforms as described 
below. Biomarkers for analysis were selected based on 
their potential to be targeted therapeutically and/or based 
on clinical evidence of a utility in other solid tumors.
Immunohistochemistry (IHC)
Protein expression was determined by IHC analysis, 
using commercially available detection kits and automated 
staining techniques (Benchmark XT, Ventana, and 
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AutostainerLink 48, Dako) [53]. Antibodies used included: 
androgen receptor (AR), topoisomerases 1 and 2 (TOPO1, 
TOPO2A) (Leica Biosystems); ER, PR, cMET, HER2 
(Ventana); cKIT, epidermal growth factor receptor (EGFR), 
phosophatase and tensin homolog (PTEN) (Dako), O(6)-
methylguanine-methyltransferase (MGMT), P-glycoprotein 
(PGP) (Invitrogen); transducin-like enhancer of split 3 
(TLE3, Santa Cruz); ribonucleotide reductase M1 (RRM1, 
Protein Tech); SPARC (monoclonal, R&D Systems; 
polyclonal, Exalpha), tubulin beta-3 chain (TUBB3) 
(Covance), Excision Repair Cross-Complementation 
Group 1 (ERCC1, (Abcam), platelet derived growth 
factor receptor alpha (PDGFRA, Thermo), Programmed 
cell death protein 1 (PD-1) and Programmed death-ligand 
1 (PD-L1) (BD Pharmingen and R&D Systems). IHC 
thresholds previously validated in other cancers were used, 
as cutoffs are not established in sarcoma (Appendix 1).
In situ hybridization
Fluorescent in-situ hybridization (FISH) was used for 
evaluation of the HER-2/neu [HER-2/CEP17 probe; HER-
2/CEP17 ratio > 2.2 was considered amplified], EGFR 
[EGFR/CEP7 probe EGFR/CEP7 ratio ≥ 2, or ≥ 15 EGFR 
copies per cell in ≥ 10% of analyzed cells was considered 
amplified], TOP2A [TOP2/CEP17 probe; TOP2A/CEP17 
ratio ≥ 2.0 was considered amplified], cMET [cMET/CEP7 
probe; cMET/CEP7 ratio ≥ 5 was considered amplified], 
ALK [Break Apart Probe; ALK rearrangements, either 
inversion or translocation of the ALK gene at 2p23, were 
identified by separation of the fusion signals into one red 
and one green signal], cMYC [cMYC/CEP8 probe; cMYC/
CEP8 ratio ≥ 2 was considered amplified], and PIK3CA 
[PIK3CA/CEP3 probe; PIK3CA/CEP3 ≥ 3 was considered 
amplified] (Abbott Molecular/Vysis). HER-2/neu and 
cMET status were more recently evaluated by chromogenic 
in-situ hybridization (INFORM HER-2 Dual ISH DNA 
Probe Cocktail; commercially available cMET and 
chromosome 7 DIG probe; Ventana), and used the same 
scoring system as for FISH.
Mutational analysis
Next-Generation Sequencing (NGS)
Direct sequence analysis was performed on genomic 
DNA isolated from FFPE tumor samples using the Illumina 
Appendix 1: IHC Thresholds
Protein Threshold for Overexpression (Intensity and %expression in tumor)
AR ≥ 1+ and ≥ 10%
cKIT ≥ 2+ and ≥ 30%
cMET ≥ 2+ and ≥ 50%
EGFR 2+ and = 10% or 1+ and < 10%; current = H-score, < 200 or ≥ 200
ER ≥ 1+ and ≥ 10%
PR ≥ 1+ and ≥ 10%
HER2 ≥ 3+ and > 10%
PD-1 ≥ 1+ (TIL Count/High power field with 40x objective)
PD-L1 ≥ 2+ and ≥ 5%
PDGFRA ≥ 2+ and 30%
PGP ≥ 1+ and ≥ 10%
SPARC ≥ 2+ and ≥ 30%
TLE3 ≥ 2+ and ≥ 30%
TOPO1 ≥ 2+ and ≥ 30%
TOP2A ≥ 1+ and ≥ 10%
TUBB3 ≥ 2+ and ≥ 30%
Protein Threshold for Loss (Intensity and %expression in tumor)
ERCC1 < 2+ or ≤ 3+ and < 10% or = 2+ and < 50%
MGMT = 0+ or ≤ 35%
PTEN = 0+ or ≤ 50%
RRM1 < 2+ or < 50%
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MiSeq platform. Average sequencing depth was > 1000X. 
Specific regions of 47 genes were amplified using the 
Illumina TruSeq Amplicon Cancer Hotspot panel.
Sanger sequencing
Prior to the availability of CLIA certified NGS, 
mutation analysis by Sanger sequencing included selected 
regions of BRAF, KRAS, cKIT, EGFR, and PIK3CA genes 
and was performed by using M13-linked PCR primers 
designed to amplify targeted sequences. PCR products were 
bi-directionally sequenced using the BigDye Terminator 
v1.1 chemistry, analyzed using the 3730 DNA Analyzer 
(Applied Biosystems). Sequence traces were analyzed 
using Mutation Surveyor software v3.25 (Soft Genetics).
Statistical analysis
The patient population and profiling data were 
characterized using standard descriptive statistics. When 
comparing data across the subtypes, groups with less than 
10 cases were not considered. For chemotherapy protein 
biomarkers, overexpression or loss in at least 60% of 
samples in a particular subtype were considered clinically 
significant (mean selected as cutoff). For targeted therapy 
protein biomarkers, overexpression in at least 17.5% of 
cases was considered clinically relevant (mean selected 
as cutoff). Concordance across platforms was determined 
using Cohen’s Kappa.
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